Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Industry Trends
  • Published:

Cancer multidrug resistance

Nature Biotechnology volume 17, pages 94–95 (1999)Cite this article

Multidrug resistance, the principal mechanism by which many cancers develop resistance to chemotherapy drugs, is a major factor in the failure of many forms of chemotherapy. It affects patients with a variety of blood cancers and solid tumors, including breast, ovarian, lung, and lower gastrointestinal tract cancers.

Tumors usually consist of mixed populations of malignant cells, some of which are drug-sensitive while others are drug-resistant. Chemotherapy kills drug-sensitive cells, but leaves behind a higher proportion of drug-resistant cells. As the tumor begins to grow again, chemotherapy may fail because the remaining tumor cells are now resistant.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Rennick, B.R. et al. 1947. J. Pharmacol. Exp. Ther. 91: 210–217.

    Google Scholar 

  2. Juliano, RL and Ling, V. 1976. Biochim. Biophys. Acta 455: 152–162.

    Article  Google Scholar 

  3. Riordan, J.R. and Ling, V. 1979. J. Biol. Chem. 254: 12701–12705.

    Google Scholar 

  4. Debenham, P.G. et al. 1982. Mol. Cell Biol. 2: 881–889.

    Article  Google Scholar 

  5. Riordan, J.R. et al. 1985. Nature 316: 817– 819.

    Article  Google Scholar 

  6. Chen, C.J. et al. 1986. Cell 47: 381– 389.

    Article  Google Scholar 

  7. Cole, S.P. et al. 1992. Science 258: 1650– 1654.

    Article  Google Scholar 

  8. Bellamy, W.T. 1996. Ann. Rev. Pharmacol. Toxixol. 36: 161–183.

    Article  Google Scholar 

  9. Kolaczkowski, M. et al. 1998. Microb. Drug. Resist. 4: 143–18.

    Article  Google Scholar 

  10. Pierre, A. et al. 1998. Cancer Chemother. Pharmacol. 42: 454–460.

    Article  Google Scholar 

  11. Persidis, A. 1998. Nat. Biotechnol. 16: 488 –489.

    Article  Google Scholar 

  12. Oshika, Y. et al. 1998. Mod. Pathol. 11: 1059– 1063.

    Google Scholar 

  13. Persidis, A. 1998. Nature Biotechnol. 16: 791 –792.

    Article  Google Scholar 

  14. Bakos, E. et al. 1998. J. Biol. Chem. 273: 32167 –32175.

    Article  Google Scholar 

  15. Weinstein, J.N. et al. 1998. Science 275: 343.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Aris Persidis is vice president for business development at Argonex Inc., 2044 India Road, Charlottesville, 22901, VA

    Aris Persidis

Authors
  1. Aris Persidis
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Persidis, A. Cancer multidrug resistance. Nat Biotechnol 17, 94–95 (1999). https://doi.org/10.1038/5289

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/5289

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing